Cancers Expressing Somatostatin Receptors, Carcinoid Cancer, Medullary Thyroid Cancer, Neuroendocrine Tumors
Conditions
Brief summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed description
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Interventions
DRUG68Ga DOTATATE
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
Sponsors
Jonsson Comprehensive Cancer Center
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Older than 18 years the time of radiotracer administration * Provides written informed consent * Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline * Able to remain still for duration of each imaging procedure (about 30 minutes)
Exclusion criteria
* Less than 18 years-old at the time of radiotracer administration * Pregnant or nursing * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
Countries
United States
Outcome results
None listed